Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Amylyx Pharmaceuticals, Inc. (AMLX) AI Forecast

Our AI analyzed Amylyx Pharmaceuticals, Inc.. Create a free account and follow it to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$AMLX Neutral Signal Full forecast available
Sign Up Free

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Forecast 2025

Amylyx Pharmaceuticals, Inc. (AMLX) AI Stock Price Forecast & Investment Analysis

Amylyx Pharmaceuticals, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Amylyx Pharmaceuticals, Inc. (AMLX) - Comprehensive Stock Analysis & Investment Research

Deep dive into Amylyx Pharmaceuticals, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 28, 2026, 10:05 p.m. (UTC)

Amylyx Pharmaceuticals, Inc. Investment Summary

When evaluating whether Amylyx Pharmaceuticals, Inc. (AMLX) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Amylyx Pharmaceuticals, Inc. (AMLX) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $2 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Amylyx Pharmaceuticals, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Amylyx Pharmaceuticals, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Amylyx Pharmaceuticals, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Amylyx Pharmaceuticals, Inc.

Sign Up Free
Corporate Identity

Amylyx Pharmaceuticals, Inc. (Stock Symbol: AMLX) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Amylyx Pharmaceuticals, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Amylyx Pharmaceuticals, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Amylyx Pharmaceuticals, Inc....

Unlock Full Company Profile

Get complete details about Amylyx Pharmaceuticals, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Amylyx Pharmaceuticals, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Amylyx Pharmaceuticals, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Amylyx Pharmaceuticals, Inc....

Unlock Financial Analysis

Get complete financial metrics for Amylyx Pharmaceuticals, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Amylyx Pharmaceuticals, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Amylyx Pharmaceuticals, Inc. strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Amylyx Pharmaceuticals, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-112 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Financial Strength & Leverage

Current ratio of 17.85 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Amylyx Pharmaceuticals, Inc. (AMLX) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Amylyx Pharmaceuticals, Inc. stock analysis.

Deep dive into Amylyx Pharmaceuticals, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Amylyx Pharmaceuticals, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Amylyx Pharmaceuticals, Inc.:

P/B Ratio 7.95x
Market Cap $2.17B
Book Value/Share $2.46
FCF/Share $-1.00
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Amylyx Pharmaceuticals, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Amylyx Pharmaceuticals, Inc.: An ROE of -70.1% indicates room for improvement in shareholder value creation.

ROE -70.1%
ROA -65.2%
ROIC -68.9%
Tax Rate -0.3%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Amylyx Pharmaceuticals, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Amylyx Pharmaceuticals, Inc.: A current ratio of 17.85 indicates strong liquidity.

Current Ratio 17.85x
D/E Ratio 0.07x
Financial Leverage 1.07x
Working Capital $269M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Amylyx Pharmaceuticals, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Amylyx Pharmaceuticals, Inc.: Free cash flow of $-112M indicates cash challenges that need attention.

Operating Cash Flow -$163M
Free Cash Flow -$112M
Capital Spending $51M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Amylyx Pharmaceuticals, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Amylyx Pharmaceuticals, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Amylyx Pharmaceuticals, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Amylyx Pharmaceuticals, Inc.:

Income Statement
Operating Income -$191M
Net Income -$191M
R&D Expense $86M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 285%
Cash & Short-term Investments 229%
Total Liabilities 20%
Short-term Debt 12%
Dividend & Shareholder Information
Shares Outstanding 111M

Latest Amylyx Pharmaceuticals, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Amylyx Pharmaceuticals, Inc. (AMLX) stock price and investment outlook.

📰 Loading...

Amylyx Pharmaceuticals, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Amylyx Pharmaceuticals, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
AARD ██% $140M x 1.6x
ABBV ██% $466.15B 128.2x x
ABCL ██% $1.61B x 1.7x
ABEO ██% $342M 5.2x 2.4x
ABT ██% $186.84B 29.8x 3.6x
ABUS ██% $869M 5.4x 3.3x
ABVC ██% $27M x 2.5x
ABVX ██% $9.76B x x
ACAD ██% $4.45B 11.9x 3.6x
ACET ██% $77M x 0.6x
ACRS ██% $744M x 5.2x
ACRV ██% $60M x 0.6x
ACUT ██% $4M x x
ACXP ██% $6M x 0.9x
ADAG ██% $246M x 6.5x
ADCT ██% $141M x x
ADIL ██% $6M x 1.7x
ADTX ██% $3M x x
ADXN ██% $7M x x
AEON ██% $11M x x
AGIO ██% $2.14B x 1.9x
AKBA ██% $340M x 12.4x
AKTX ██% $15M x 1.0x
ALDX ██% $95M x 2.3x
ALKS ██% $8.46B 128.0x 4.7x
ALLR ██% $19M x 2.7x
ALMS ██% $3.38B x 6.0x
ALNY ██% $38.18B 121.7x 48.4x
ALT ██% $581M x 2.1x
ALXO ██% $268M x 1.8x
ALZN ██% $5M x 6.8x
AMLX ██% $2.17B x 8.0x
AMPH ██% $899M 11.4x 1.2x
AMRN ██% $293M x 0.7x
AMRX ██% $5.93B 48.6x x
ANAB ██% $1.51B x 118.7x
ANEB ██% $14M x 1.7x
ANIP ██% $1.69B 18.4x 3.0x
ANIX ██% $119M x 8.3x
ANNX ██% $757M x 3.7x
ANRO ██% $961M x 4.0x
ANTX ██% $169M x 2.1x
ANVS ██% $72M x 23.0x
APLM ██% $40M x x
APRE ██% $7M x 0.2x
APUS ██% $12M x 0.1x
APVO ██% $5M x 0.4x
AQST ██% $467M x x
ARCT ██% $163M x 0.9x
ARDX ██% $1.26B x 8.5x
ARQT ██% $3.55B x 18.7x
ARTL ██% $3M x 0.5x
ARVN ██% $529M x 1.4x
ARWR ██% $12.06B x 19.6x
ASBP ██% $9M x 2.4x
ASMB ██% $507M x 2.6x
ASND ██% $15.77B x x
ASRT ██% $151M x 2.0x
ATAI ██% $2.66B x 16.6x
ATHE ██% $83M x x
ATNM ██% $27M x 11.8x
ATOS ██% $24M x 0.8x
ATXI ██% $820K x 0.7x
AUPH ██% $1.96B 6.6x 3.5x
AVBP ██% $1.36B x 4.2x
AVIR ██% $361M x 1.5x
AVTX ██% $1.02B x 15.0x
AXIM ██% $1M x x
AXSM ██% $12.04B x 220.6x
AZTR ██% $2M x 0.2x
BBIO ██% $16.46B x x
BBOT ██% $688M x 1.9x
BCAX ██% $1.82B x 3.6x
BCTX ██% $31M x 1.3x
BCYC ██% $275M x 0.5x
BDPT ██% $20K x x
BDRX ██% $1M x x
BFRG ██% $11M x 2.3x
BFRI ██% $12M x 2.1x
BHC ██% $1.69B x x
BHST ██% $46M x 1.8x
BIOA ██% $927M x 2.4x
BIOE ██% $13M 9.7x x
BIOM ██% $510K x x
BIVI ██% $10M x 0.7x
BIXT ██% $3M x x
BLRX ██% $13M x x
BLTE ██% $6.11B x 7.9x
BMEA ██% $91M x 4.9x
BMRN ██% $11.65B 43.3x 1.9x
BMY ██% $127.50B 17.5x 6.4x
BNTC ██% $414M x 2.3x
BOLD ██% $56M x 0.6x
BOLT ██% $8M x 0.4x
BPTH ██% $2M x x
BQST ██% $2M x x
BRNS ██% $25M x 0.4x
BSPK ██% $10K x x
BTAI ██% $27M x x
BYSI ██% $48M x x
CALC ██% $11M x x
CANF ██% $7M x 1.2x
CAPR ██% $403M x 1.5x
CATX ██% $322M x 0.9x
CBIO ██% $626M x 6.2x
CDT ██% $2M x x
CING ██% $61M x 3.2x
CLCS ██% $65M x x
CLNN ██% $64M x x
CLRB ██% $20M x 5.9x
CLSDQ ██% $1M x x
CLYM ██% $732M x 5.0x
CMMB ██% $10M x 0.8x
CMND ██% $2M x x
CMPS ██% $1.52B x 4.7x
CNBX ██% N/A x x
CNSP ██% $7M x 104.8x
CNTA ██% $6.27B x 12.9x
CNTB ██% $132M x 3.1x
CNTX ██% $57M x 1.1x
COCP ██% $13M x 3.2x
COGT ██% $6.91B x 11.4x
COLL ██% $1.16B 15.5x 3.7x
CORT ██% $9.52B 201.0x 14.9x
COYA ██% $100M x 2.0x
CPHI ██% $50M x 1.4x
CPIX ██% $103M x 4.8x
CPMD ██% $1M x x
CPRX ██% $3.85B 17.4x 3.8x
CRBP ██% $161M x 1.3x
CRMD ██% $596M 3.3x 1.4x
CRNX ██% $8.83B x 6.9x
CRVO ██% $25M x 2.3x
CRVS ██% $1.09B x 4.5x
CTMX ██% $708M x 2.2x
CTNM ██% $518M x 2.1x
CTOR ██% $52M x 1.5x
CTTH ██% $4M x 5.3x
CTXR ██% $14M x 0.2x
CUE ██% $131M x 6.1x
CURX ██% $5M x 0.6x
CVKD ██% $6M x 3.6x
CVSI ██% $4M x 2.6x
CYCN ██% $15M x 2.2x
CYDY ██% $270M x x
CYPH ██% $67M x 0.8x
CYRX ██% $766M 9.6x 1.6x
CYTK ██% $10.95B x x
DARE ██% $19M x 26.2x
DCOY ██% $2M x 0.5x
DERM ██% $174M x 5.6x
DMAC ██% $363M x 7.7x
DMRA ██% $1.80B x 3.5x
DNTH ██% $5.70B x 4.8x
DRMA ██% $5M x 0.8x
DRUG ██% $706M x x
DSGN ██% $742M x 3.4x
DWTX ██% $51M x 0.6x
DYN ██% $4.23B x 4.9x
EBS ██% $380M x 0.7x
EDSA ██% $48M x 4.7x
ELAB ██% $4M x 0.3x
ELAN ██% $12.69B x 2.0x
ELDN ██% $271M x 6.1x
ELTP ██% $409M 9.1x 4.1x
ELTX ██% $79M x x
ELVN ██% $3.77B x 8.3x
EMMA ██% $820K x x
ENLV ██% $72M 0.0x 0.0x
ENSC ██% $4M x x
ENTA ██% $370M x 3.2x
ENVB ██% $5M x 1.1x
EOLS ██% $401M x x
EPRX ██% $403M x 4.9x
EQ ██% $149M x 2.5x
ERAS ██% $6.55B x 16.6x
ERNA ██% $5M x 0.7x
ESPR ██% $799M x x
ETON ██% $1.16B x 37.8x
ETST ██% $35M 7.2x 5.0x
EVFM ██% $1M x x
EVMN ██% $413M x 1.4x
EWTX ██% $4.35B x 8.8x
FBIO ██% $109M 0.9x 0.7x
FBLG ██% $3M x 1.3x
FBRX ██% $1.57B x 37.3x
FHTX ██% $305M x x
FLNA ██% $44M x 0.6x
FTH ██% $754M x x
FULC ██% $248M x 0.7x
GALT ██% $223M x x
GANX ██% $79M x 5.6x
GCAN ██% $260K x x
GDTC ██% $11M x x
GERN ██% $956M x 4.2x
GHRS ██% $1.73B x x
GLMD ██% $3M x 0.2x
GLSI ██% $197M x 37.4x
GNLX ██% $132M x 5.8x
GNPX ██% $4M x 0.2x
GOSS ██% $97M x x
GOVX ██% $4M x 2.3x
GPCR ██% $3.46B x 2.4x
GRCE ██% $38M x 0.6x
GRI ██% $2M x 0.2x
GRTX ██% $3.38B 22.7x 4646.0x
GSK ██% $104.11B x x
GTBP ██% $12M x 1.6x
GYRE ██% $683M x 6.8x
HCM ██% $1.92B 2.1x 1.6x
HCWB ██% $4M x 0.8x
HELP ██% $477M x x
HEPA ██% $1M x 0.7x
HIND ██% $14M x 2.1x
HOOK ██% $14M x 0.4x
HOWL ██% $22M x 1.8x
HRMY ██% $2.06B 14.2x 2.3x
HRTX ██% $87M x 9.6x
HSTC ██% $99M x 79.9x
HURA ██% $141M x 6.1x
HYFT ██% $67M x x
HYPD ██% $39M x 0.7x
IBIO ██% $72M x 0.9x
IBO ██% $47M x 4.1x
IDYA ██% $3.16B x 3.4x
IFRX ██% $250M x x
IGC ██% $26M x 4.2x
IMMP ██% $56M x x
IMMX ██% $619M x 7.3x
IMNM ██% $2.56B x 4.3x
IMNN ██% $6M x 1.8x
IMRN ██% $9M x x
IMRX ██% $282M x 1.4x
IMUX ██% $188M x 1.2x
INBP ██% $5M x 0.3x
INDP ██% $272M x 217.8x
INDV ██% $4.96B 19.7x x
INM ██% $9M x 1.3x
INO ██% $80M x 13.2x
INSM ██% $22.68B x 32.2x
INTI ██% $14M x x
INVA ██% $1.62B 3.2x 1.2x
IOBTQ ██% $70K x 0.1x
IONS ██% $9.28B x 18.9x
IRD ██% $277M x x
IRON ██% $2.82B x 4.1x
IRWD ██% $644M 6.3x x
ISCO ██% $2M x x
IVA ██% $1.09B x x
IXHL ██% $36M x 0.5x
JAGX ██% $5M x x
JANX ██% $948M x 1.0x
JAZZ ██% $15.81B 536.1x 3.5x
JBIO ██% $1.21B x 4.1x
JNJ ██% $640.25B 30.4x 7.5x
JUNS ██% $6M x x
KALA ██% $12M x 1.2x
KALV ██% $1.38B x x
KAPA ██% $7M x 1.3x
KAYS ██% $210K x x
KMDA ██% $403M x x
KNSA ██% $4.86B 66.5x 8.0x
KPRX ██% $10M x 0.7x
KPTI ██% $160M x x
KROS ██% $201M x 0.7x
KRRO ██% $155M x 1.3x
KTTA ██% $15M x 0.3x
KURA ██% $825M x 7.6x
KYNB ██% $29M 0.2x x
LAB ██% $300M 3.8x 0.5x
LBRX ██% $997M x 2.6x
LEGN ██% $3.73B x x
LEXX ██% $13M x 2.7x
LFCR ██% $163M x x
LFVN ██% $80M 10.2x 2.4x
LGND ██% $5.96B 38.8x 6.0x
LGVN ██% $19M x 1.2x
LIANY ██% $12M x 0.1x
LIFD ██% $3M x 0.4x
LIPO ██% $150K x 0.1x
LITS ██% $34M x 0.6x
LIXT ██% $120M x 15.2x
LKFT ██% $1.85B x x
LLY ██% $1.09T 43.3x 35.1x
LNAI ██% $10M x x
LPCN ██% $16M x 0.7x
LQDA ██% $7.46B 334.2x 68.7x
LRMR ██% $394M x 2.5x
LSTA ██% $13M x 1.2x
LTRN ██% $36M x 10.3x
LXRX ██% $994M x 4.9x
LYEL ██% $302M x 1.1x
MAIA ██% $78M x 2.8x
MANE ██% $4.65B x 11.9x
MBIO ██% $4M x 0.5x
MBRX ██% $15M x 1.0x
MBX ██% $2.92B x 6.7x
MCRB ██% $47M x 1.8x
MDCX ██% $18M x 13.6x
MDGL ██% $12.70B x 23.4x
MGNX ██% $254M x 12.0x
MIRA ██% $37M x 4.0x
MIRM ██% $6.96B x 28.7x
MIST ██% $133M x 3.7x
MLTX ██% $1.69B x 6.7x
MLYS ██% $2.24B x 3.5x
MNKD ██% $1.22B x x
MNOV ██% $65M x 1.7x
MNPR ██% $739M x 5.5x
MPLT ██% $448M x 1.1x
MREO ██% $48M x 1.4x
MRK ██% $323.24B 36.2x 7.1x
MRKR ██% $20M x 1.5x
MRVI ██% $2.47B x 11.7x
MSLE ██% $197M x x
MTNB ██% $2M x 0.7x
MTVA ██% $7M x 0.8x
NAMS ██% $3.52B x 5.3x
NATR ██% $362M 18.2x 2.2x
NBP ██% $206M x 0.8x
NBTX ██% $1.95B x x
NCEL ██% $19M x 35.7x
NCNA ██% $5M x x
NERV ██% $184M x x
NEUP ██% $21M x 0.7x
NGNE ██% $691M x 2.9x
NIKA ██% $806M x x
NKTR ██% $2.41B x 4.2x
NKTX ██% $168M x 0.6x
NMAD ██% $81M x 10.2x
NNVC ██% $39M x 4.3x
NRIX ██% $2.43B x 6.0x
NRSN ██% $21M x x
NRXP ██% $155M x x
NSRX ██% $36M x 13.1x
NTHI ██% $85M x x
NUVB ██% $2.31B x 7.2x
NUVL ██% $9.75B x 8.3x
NVCT ██% $616M x 43.3x
NVS ██% $297.88B x x
NWBO ██% $273M x x
NXTC ██% $21M x 0.8x
NXTS ██% $2M x 0.2x
OCUL ██% $1.89B x 3.3x
OGEN ██% $2M x 0.4x
OGI ██% $132M x x
OGN ██% $3.56B 14.5x 3.9x
OKUR ██% $164M x 0.9x
OLMA ██% $1.05B x 2.2x
OMER ██% $816M 9.5x x
ONC ██% $33.81B 65.9x 7.1x
ONCO ██% $3M x 0.3x
ONCY ██% $93M x x
OPK ██% $937M x 0.8x
ORGO ██% $328M 120.7x 1.3x
ORIC ██% $1.24B x 3.0x
ORKA ██% $5.44B x 11.2x
ORMP ██% $170M 1.6x 0.7x
OSTX ██% $70M x x
OTLC ██% $18M x 0.1x
OVID ██% $439M x 2.2x
OWPC ██% $70K x x
PAHC ██% $1.43B 15.0x 4.0x
PBH ██% $2.44B 12.8x 1.3x
PBM ██% $12M x x
PBYI ██% $407M 16.7x 3.2x
PCRX ██% $1.04B 202.5x 1.6x
PCSA ██% $7M x 2.7x
PCYN ██% $2M x 1.0x
PDSB ██% $39M x 9.9x
PEPG ██% $131M x 1.0x
PFE ██% $140.40B 18.7x 1.6x
PGEN ██% $1.93B x 95.3x
PHAT ██% $949M x x
PHIO ██% $12M x 0.7x
PHVS ██% $2.37B x x
PKTX ██% $3M x 10.3x
PLRX ██% $67M x 0.4x
PLYX ██% $93M x 37.3x
PMHS ██% $2M x x
PMN ██% $105M x 1.7x
PMVP ██% $63M x 0.7x
PPBT ██% $1M x x
PPCB ██% $3M x 0.3x
PRAX ██% $8.80B x 6.2x
PRFX ██% $3M x 0.4x
PRGO ██% $1.40B x 0.6x
PRLD ██% $321M x 5.3x
PRPH ██% $840K x 0.1x
PRQR ██% $244M x x
PRTA ██% $462M x 1.5x
PTCT ██% $6.28B x x
PTGX ██% $8.71B x 13.3x
PTIX ██% $420K x x
PTN ██% $14M x 1.3x
PTPI ██% $170K 0.0x 0.1x
PULM ██% $6M x 1.8x
PVCT ██% $25M x x
PVLA ██% $2.03B x 8.7x
PYXS ██% $183M x 5.9x
QNRX ██% $9M x 1.0x
QNTM ██% $19M x x
QTTB ██% $452M 13.6x 9.8x
QUCY ██% $25M x 5.5x
QURE ██% $2.41B x 16.1x
RADX ██% $29M x x
RANI ██% $111M x 3.9x
RAPP ██% $2.01B x 4.3x
RARE ██% $2.64B x x
RCKT ██% $355M x 1.5x
RCUS ██% $3.49B x 6.7x
RDY ██% $9.82B x x
REGN ██% $69.39B 15.7x 2.2x
REVB ██% $4M x 0.3x
RFL ██% $121M x 1.6x
RGBP ██% $50K x x
RIGL ██% $688M 1.9x 1.7x
RKTO ██% $17M x 4.1x
RLMD ██% $546M x 2.5x
RLYB ██% $86M x 1.7x
RMHI ██% $25M x x
RMTI ██% $29M x 0.8x
RNAC ██% $212M x x
RNAZ ██% $5M x 4.0x
RNTX ██% $67M x 5.8x
RNXT ██% $42M x 3.7x
ROIV ██% $25.01B x 5.5x
RPRX ██% $33.82B 40.9x 4.9x
RTEZ ██% $1.93B x x
RVPH ██% $7M x 0.4x
RVRC ██% $101M x 16.5x
RYTM ██% $7.26B x 59.1x
RZLT ██% $478M x 4.1x
SBFM ██% $2M x 0.1x
SCNX ██% $15M x 0.2x
SCYX ██% $284M x 6.9x
SDEV ██% $30M 0.1x 0.2x
SDGR ██% $1.13B x 3.6x
SEPN ██% $1.50B x 4.0x
SER ██% $31M x 1.8x
SGMT ██% $460M x 4.5x
SHPH ██% $2M x 0.5x
SIGA ██% $222M 11.0x 1.5x
SILO ██% $5M x 0.9x
SION ██% $2.05B x 7.1x
SKVI ██% $1M x x
SKYE ██% $22M x 2.4x
SLGL ██% $259M x 11.4x
SLN ██% $570M x 11.5x
SLS ██% $1.97B x 18.3x
SMMT ██% $10.39B x 16.5x
SMNR ██% $145M x x
SNDX ██% $1.80B x 43.1x
SNGX ██% $5M x 1.7x
SNSE ██% $31M x x
SNY ██% $108.63B x x
SPRB ██% $116M x 3.3x
SPRC ██% $3M x x
SPRO ██% $70M 4.6x 1.3x
SPRY ██% $572M x 9.3x
SRPT ██% $1.67B 25.8x 1.1x
STOK ██% $1.85B x 4.7x
STTK ██% $670M x 7.0x
SUPN ██% $2.73B x 2.5x
SVRA ██% $1.10B x 6.2x
SXTP ██% $4M x 0.8x
SYBX ██% $7M x 0.6x
SYRE ██% $7.58B x 11.3x
TAK ██% $56.43B x x
TBPH ██% $870M 7.6x 3.0x
TCRT ██% $4M x 3.5x
TELO ██% $82M x 16.5x
TENX ██% $411M x 3.6x
TEVA ██% $36.52B 23.3x 4.4x
TGTX ██% $8.54B 18.5x 14.7x
TLPH ██% $63M x 3.4x
TLX ██% $3.41B x x
TNGX ██% $4.16B x 10.6x
TNXP ██% $161M x 0.7x
TOVX ██% $10M x 0.6x
TPST ██% $15M x 17.9x
TRDA ██% $228M x 0.8x
TRVI ██% $2.32B x 13.5x
TTRX ██% $238M x 38.9x
TVRD ██% $23M x 1.6x
TVTX ██% $5.16B x 52.2x
TXMD ██% $24M 131.9x 0.9x
TYRA ██% $1.85B x 4.8x
UNCY ██% $126M x 3.4x
UPB ██% $333M x 1.1x
URGN ██% $1.99B x x
UTHR ██% $26.28B 20.4x 4.5x
VBIO ██% $890K x 0.1x
VCNX ██% $3M x x
VERA ██% $2.40B x 4.8x
VGLS ██% $240K x x
VICP ██% $47M x x
VKTX ██% $3.84B x 7.6x
VNDA ██% $308M x 1.1x
VRCA ██% $99M x 6.2x
VRDN ██% $1.99B x 3.1x
VREOD ██% $491M x 1.7x
VREOF ██% $491M x 1.7x
VRTX ██% $122.80B 28.3x 6.3x
VSTM ██% $542M x 6.6x
VTGN ██% $9M x 0.3x
VTRS ██% $20.60B x 1.4x
VYNE ██% $19M x 0.8x
WHWK ██% $166M x 1.4x
WVE ██% $1.13B x 2.2x
XBIO ██% $6M x 0.8x
XBIT ██% $70M x 0.5x
XCUR ██% $10M x 5.0x
XENE ██% $6.29B x 4.7x
XERS ██% $1.43B 118.9x 109.8x
XLO ██% $60M x 0.8x
XNCR ██% $1.44B x 2.8x
XOMA ██% $710M 21.0x 7.7x
XTLB ██% $7M x x
ZBIO ██% $2.03B x 6.0x
ZLAB ██% $2.10B x 3.2x
ZNTL ██% $322M x 1.8x
ZTS ██% $32.57B 12.3x 10.1x
ZVRA ██% $568M 4.6x 2.8x
ZVSA ██% $940K x x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Amylyx Pharmaceuticals, Inc. Stock Forecast

How accurate are Amylyx Pharmaceuticals, Inc. stock predictions?

Our AI model shows a -22% Spearman correlation coefficient for AMLX predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Amylyx Pharmaceuticals, Inc. stock price forecasts?

Our analysis considers Amylyx Pharmaceuticals, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Amylyx Pharmaceuticals, Inc. a good investment in 2025?

Based on our AI analysis, Amylyx Pharmaceuticals, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Amylyx Pharmaceuticals, Inc. forecasts updated?

Amylyx Pharmaceuticals, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Amylyx Pharmaceuticals, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...